COMPANY STATEMENT

June 28, 2023

Bard Statement on PowerPort™ Litigation

Patient safety and product quality are top priorities, and we are empathetic to any patient who experiences a medical complication following the use of one of our devices. All implantable medical devices — including vascular access port devices — carry inherent risks but also offer important clinical benefits that can outweigh those risks. All of our PowerPort™ devices are cleared for use by the U.S. Food and Drug Administration (FDA), and we are confident in both their design and the appropriateness of our communication of their risks and benefits.

It is important to note that there has been no recall of any of our PowerPort™ devices due to catheter fracture. The complications alleged in recent legal filings are known risks that are communicated to health care practitioners in our PowerPort™ instructions for use (IFU). We clearly communicate the risks and benefits of our PowerPort™ devices so physicians, in consultation with their patients, can determine whether those benefits outweigh the potential risks in a particular instance. Bard's PowerPort™ devices have benefited countless patients, which is why we have remained the category leader in the port industry for more than 30 years.

# # #